Concepedia

Dose-proportionality Analysis

Dose-Proportionality Analysis is a pharmacokinetic evaluation method used in noncompartmental analysis to determine whether the exposure to a drug, typically measured as area under the concentration-time curve or maximum observed concentration, increases in direct proportion to the administered dose across different dosage levels.

63

Publications

10K

Citations

272

Authors

105

Institutions

Publications per year

2017–2026

6

Variants

Dose Proportionality Analysis

Parents

Children

Publications

63

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Ting‐Chao Chou, Paul Talalay · Advances in Enzyme Regulation · 1984 · 7.2K citations

, , +16

Confidence Interval Criteria for Assessment of Dose Proportionality

Brian P. Smith · Pharmaceutical Research · 2000 · 352 citations

, , +13

A Non-Parametric Equivalent of Williams' Test for Contrasting Increasing Dose Levels of a Treatment

Eryl A. C. Shirley · Biometrics · 1977 · 325 citations

, , +16

Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party

Kevin Gough, Michael G. Hutchison, Oliver N. Keene et al. · Drug Information Journal · 1995 · 266 citations

, , +12

SIMPLIFICATION OF DRUG DOSAGE CALCULATION BY APPLICATION OF THE SURFACE AREA PRINCIPLE

John D. Crawford, Mary E. Terry, G. Margaret Rourke · PEDIATRICS · 1950 · 169 citations

, , +16

1–5 of 63

Authors

272

  1. SA
    Silke Appel‐Dingemanse

    Novartis (Switzerland), Switzerland

    2 publications · 30 citations

    2

    h-index

  2. FP
    F. Pommier

    Novartis (Switzerland), Switzerland

    2 publications · 30 citations

    2

    h-index

  3. JM
    Jack M. Curtis

    United States Food and Drug Administration, United States

    2 publications · 94 citations

    2

    h-index

  4. LS
    Lisa Squassante

    GlaxoSmithKline (Italy), Italy

    2 publications · 54 citations

    2

    h-index

  5. LF
    Lila F. Knudsen

    United States Food and Drug Administration, United States

    2 publications · 94 citations

    2

    h-index

1–5 of 272

Institutions

105

  1. Novartis (Switzerland)

    Basel, Switzerland

    5 h-index

    13 publications

    188 citations

  2. Research Triangle Park Foundation

    Durham, United States

    3 h-index

    4 publications

    86 citations

  3. United States Food and Drug Administration

    Silver Spring, United States

    3 h-index

    5 publications

    222 citations

  4. Tris Pharma (United States)

    Monmouth Junction, United States

    2 h-index

    3 publications

    62 citations

  5. Novartis (France)

    Rueil-Malmaison, France

    2 h-index

    2 publications

    30 citations

  6. University of Massachusetts Amherst

    Amherst Center, United States

    2 h-index

    4 publications

    107 citations

  7. AstraZeneca (United Kingdom)

    Cambridge, United Kingdom

    2 h-index

    6 publications

    776 citations

  8. Merck & Co., Inc., Rahway, NJ, USA (United States)

    Rahway, United States

    2 h-index

    19 publications

    722 citations

1–8 of 105

Venues

  1. The Journal of Clinical Pharmacology

    5 publications · 156 citations

    5

    h-index

  2. European Journal of Clinical Pharmacology

    3 publications · 66 citations

    3

    h-index

  3. Biometrics

    3 publications · 427 citations

    3

    h-index

  4. Drug Information Journal

    DIA · 2 publications · 278 citations

    2

    h-index

  5. Clinical Drug Investigation

    2 publications · 26 citations

    2

    h-index

1–5